Phillip Wong

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5439881/publications.pdf

Version: 2024-02-01

28 papers	16,373 citations	257450 24 h-index	526287 27 g-index
28 all docs	28 docs citations	28 times ranked	23940 citing authors

#	Article	IF	Citations
1	Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma. Nature Communications, 2022, 13, 1935.	12.8	37
2	Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/â˜' trastuzumab in patients with breast cancer brain metastases. Npj Breast Cancer, 2022, 8, 50.	5.2	17
3	Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2022, 28, 3990-4002.	7.0	15
4	Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repairâ€"proficient Metastatic Colorectal Cancer. Clinical Cancer Research, 2021, 27, 2200-2208.	7.0	51
5	Inherited PD-1 deficiency underlies tuberculosis and autoimmunity in a child. Nature Medicine, 2021, 27, 1646-1654.	30.7	65
6	LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade. Science Translational Medicine, 2021, 13, .	12.4	54
7	Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study. Clinical Cancer Research, 2020, 26, 5609-5620.	7.0	32
8	Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring. Nature Medicine, 2020, 26, 1114-1124.	30.7	216
9	A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma. Clinical Cancer Research, 2020, 26, 3193-3201.	7.0	27
10	PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance. Nature Immunology, 2019, 20, 1231-1243.	14.5	217
11	PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients. Cancer Cell, 2018, 34, 775-791.e3.	16.8	170
12	Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients. European Journal of Cancer, 2017, 73, 61-70.	2.8	88
13	T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature, 2017, 545, 60-65.	27.8	1,280
14	Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab. Clinical Cancer Research, 2016, 22, 4848-4858.	7.0	146
15	A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling. Clinical Cancer Research, 2016, 22, 5729-5737.	7.0	175
16	Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy. Cancer Immunology Research, 2016, 4, 835-844.	3.4	138
17	Melanoma and immunotherapy bridge 2015. Journal of Translational Medicine, 2016, 14, 65.	4.4	12
18	Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab. Clinical Cancer Research, 2016, 22, 2908-2918.	7.0	459

#	Article	IF	Citations
19	Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma. , 2015, 3, 23.		190
20	Mutational landscape determines sensitivity to PD-1 blockade in nonâ€“small cell lung cancer. Science, 2015, 348, 124-128.	12.6	6,756
21	Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma. New England Journal of Medicine, 2014, 371, 2189-2199.	27.0	3,753
22	Rapid Development of T Cell Memory. Journal of Immunology, 2004, 172, 7239-7245.	0.8	55
23	Disparate In Vitro and In Vivo Requirements for IL-2 During Antigen-Independent CD8 T Cell Expansion. Journal of Immunology, 2004, 172, 2171-2176.	0.8	32
24	Targeted deletion of T-cell clones using alpha-emitting suicide MHC tetramers. Blood, 2004, 104, 2397-2402.	1.4	34
25	CD8 T CELLRESPONSES TOINFECTIOUSPATHOGENS. Annual Review of Immunology, 2003, 21, 29-70.	21.8	367
26	Feedback Regulation of Pathogen-Specific T Cell Priming. Immunity, 2003, 18, 499-511.	14.3	166
27	In Vivo Depletion of CD11c+ Dendritic Cells Abrogates Priming of CD8+ T Cells by Exogenous Cell-Associated Antigens. Immunity, 2002, 17, 211-220.	14.3	1,579
28	Cutting Edge: Antigen-Independent CD8 T Cell Proliferation. Journal of Immunology, 2001, 166, 5864-5868.	0.8	242